SOMAVERT (pegvisomant)
GROWTH HORMONE RECEPTOR ANTAGONISTS · ACROMEGALY
Pfizer Laboratories
Drug class
Growth Hormone Receptor Antagonists
Growth hormone receptor antagonists are a class of endocrine agents that bind to cell-surface growth hormone receptors, competitively inhibiting the binding of endogenous growth hormone and preventing receptor dimerization and downstream intracellular signaling. Read more about Growth Hormone Receptor Antagonists
1 drugs in this class 1 manufacturers
Drugs in Growth Hormone Receptor Antagonists
Filter & compare in the drug finder →
Opens the drug finder with Growth Hormone Receptor Antagonists preselected. Add indication or manufacturer filters there.
Growth hormone receptor antagonists are a class of endocrine agents that bind to cell-surface growth hormone receptors, competitively inhibiting the binding of endogenous growth hormone and preventing receptor dimerization and downstream intracellular signaling.
By blocking these peripheral receptor actions, they suppress the hepatic synthesis and secretion of insulin-like growth factor-1 (IGF-1) without directly reducing pituitary growth hormone secretion.
Clinically, this class—exemplified by pegvisomant—is indicated for the management of acromegaly, particularly in adult patients who have had an inadequate response to surgery or radiation therapy, or for whom these interventions are not appropriate.
-
fda.gov
Growth hormone receptor antagonists are a class of endocrine agents that bind to cell-surface growth hormone receptors, competitively inhibiting the binding of endogenous growth hormone and preventing receptor dimerization and downstream intracellular signaling Clinically, this class—exemplified by pegvisomant—is indicated for the management of acromegaly, particularly in adult patients who have had an inadequate response to surgery or radiation therapy, or for whom these interventions are not a...
-
nih.gov
Growth hormone receptor antagonists are a class of endocrine agents that bind to cell-surface growth hormone receptors, competitively inhibiting the binding of endogenous growth hormone and preventing receptor dimerization and downstream intracellular signaling
-
drugbank.com
By blocking these peripheral receptor actions, they suppress the hepatic synthesis and secretion of insulin-like growth factor-1 (IGF-1) without directly reducing pituitary growth hormone secretion
-
superpower.com
By blocking these peripheral receptor actions, they suppress the hepatic synthesis and secretion of insulin-like growth factor-1 (IGF-1) without directly reducing pituitary growth hormone secretion
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.